MARKET

NBIX

NBIX

Neurocrine Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

86.24
+1.64
+1.94%
Opening 11:45 05/25 EDT
OPEN
84.57
PREV CLOSE
84.60
HIGH
87.27
LOW
84.57
VOLUME
192.54K
TURNOVER
10.56M
52 WEEK HIGH
108.02
52 WEEK LOW
71.88
MARKET CAP
8.24B
P/E (TTM)
118.33
1D
5D
1M
3M
1Y
5Y
Neurocrine Biosciences to repurchase $179.4M of 2.25% Convertible Senior Notes due 2024
Neurocrine Biosciences (NASDAQ:NBIX) plans to repurchase ~$179.4M aggregate principal amount of its existing 2.25% Convertible Senior Notes due 2024. It entered into separate, privately negotiated transactions with certain holders of
Seekingalpha · 5h ago
Neurocrine Biosciences to Repurchase $179.4 Million of Convertible Notes
MT Newswires · 12h ago
BRIEF-Neurocrine Biosciences Says Entered In Transactions With Holders Of Existing 2.25% Convertible Senior Notes Due 2024 To Repurchase $179.4 Mln
reuters.com · 13h ago
BRIEF-Neurocrine Biosciences Presents New Valbenazine Data At American Psychiatric Association Annual Meeting
reuters.com · 2d ago
Neurocrine Biosciences Highlights Presentation Of New INGREZZA Data On Tardive Dyskinesia Improvement, Stability Of Psychiatric Symptoms At American Psychiatric Association Meeting Jun. 7-10
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it will present data on the use of INGREZZA® (valbenazine) capsules for the treatment of tardive dyskinesia (TD) at the American Psychiatric
Benzinga · 2d ago
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data on the use of INGREZZA® (valbenazine) capsules for the treatment of tardive dyskinesia (TD) at the American Psychiatric Association (APA) Annual Meeting being held in per...
PR Newswire · 2d ago
Neurocrine Biosciences Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60 million, a 0.45% change since Q4.
Benzinga · 6d ago
Neurocrine Biosciences valbenazine gets FDA orphan drug status for Huntington disease
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Neurocrine Biosciences' (NASDAQ:NBIX) valbenazine to treat Huntington disease (HD). The company said treatment of chorea associated with HD is
Seekingalpha · 05/13 10:08
More
No Data
Learn about the latest financial forecast of NBIX. Analyze the recent business situations of Neurocrine Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 26 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

30.77%Strong Buy
30.77%Buy
34.62%Hold
3.85%Under-perform
0.00%Sell
Analyst Price Target
The average NBIX stock price target is 112.76 with a high estimate of 150.00 and a low estimate of 75.00.
High150.00
Average112.76
Low75.00
Current 86.24
EPS
Actual
Estimate
0.090.250.420.58
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 577
Institutional Holdings: 103.33M
% Owned: 108.11%
Shares Outstanding: 95.58M
TypeInstitutionsShares
Increased
138
7.06M
New
72
2.29M
Decreased
141
9.58M
Sold Out
52
685.99K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.67%
Pharmaceuticals & Medical Research
-0.28%
Key Executives
Non-Executive Chairman/Independent Director
William Rastetter
Chief Executive Officer/Director
Kevin Gorman
Chief Financial Officer
Matthew Abernethy
Chief Human Resource Officer
Julie Cooke
Chief Scientific Officer
Jude Onyia
Other
Eric Benevich
Other
David Boyer
Other
Kyle Gano
Other
Dimitri Grigoriadis
Other
Malcolm Lloydsmith
Other
Eiry Roberts
Secretary
Darin Lippoldt
Independent Director
Gary Lyons
Independent Director
Johanna Mercier
Independent Director
George Morrow
Independent Director
Leslie Norwalk
Independent Director
Richard Pops
Independent Director
Shalini Sharp
Independent Director
Stephen Sherwin
No Data
No Data
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing, and delivering treatments for people with neurological, endocrine and psychiatric disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids, and clinical programs in multiple therapeutic areas. The Company's product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 milligram (mg) and 80 mg capsules). ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease. ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.

Webull offers kinds of Neurocrine Biosciences, Inc. stock information, including NASDAQ:NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBIX stock methods without spending real money on the virtual paper trading platform.